FLT3 Gene Mutations in Acute Myeloid Leukemia Patients in Northeast Thailand

24 November 2022 : Clinical Research

Nang Ei Ei Aung^1BCD, Supawadee Yamsri^2ACDE*, Nattiya Teawtrakul^3B, Piyawan Kamsaen^4B, Supan Fucharoen

^2DG

DOI: 10.12659/MSMBR.937446

Med Sci Monit Basic Res 2022; 28:e937446

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 1 Characteristics and laboratory data of 65 newly diagnosed acute myeloid leukemia (AML) patients according to type of FLt3 mutation.

Characteristics	Mutations in patients with AML
Characteristics	Wild type (n=48)	All mutations (n=17)	FLT3-ITD (n=10)	FLT3-TKD (n=6)	Dual ITD & TKD* (n=1)
Sex
Male; n (%)	13 (27.1)	4 (23.5)	2 (20)	1 (16.7)	1 (100)
Female; n (%)	35 (72.9)	13 (76.5)	8 (80)	5 (83.3)	–
Age
Median	43	49	57.5	44	59
IQRs	18.3–61.5	18.3–63.2	24.5–66.5	14.5–52.6	–
Number of adult (>18 y)	36	13	8	4	1
Number of children (≤18 y)	12	4	2	2	–
WBC (×10/μL)
Median	14.7	34.0^**	90.3^**	17.3	89.4
IQR	4.9–24.3	13.3–193.3	26.6–535.0	8.3–75.4	–
Hemoglobin (g/dL)
Median	8.2	7.0	6.4	8.4	7.8
IQR	7.0–9.2	5.7–8.4	5.4–8.5	6.2–8.4	–
Platelets count (×10/μL)
Median	69	36	36	47	38
IQRs	41.3–145.0	19.0–47.0	21.0–40.5	19.0–120.0	–
Peripheral blood blast (%)
Median	43	40.5	80^**	13^**	93
IQRs	21.0–69.0	10.8–91.8	49.8–97.3	3.8–17.7	–
Bone marrow blast (%)
Median	51^a	82.4^b	82.8,^c	82.4^d	82
IQRs	33.9–77.8	56.7–82.8	69.0–90.6	33.9–59.5	–
Overall survival (days)
Median	36	18	21.5	11	11
IQRs	23.0–135.5	7.0–180.0	9.8–141.3	5.0–183.0	–
FAB subtype
AML-M3; N (%)	7 (14.6)	5 (29.4)	3 (30)	2 (33.3)	–
AML-non-M3; N (%)	41 (85.4)	12 (70.6)	7 (70)	4 (66.7)	1 (100)
^* Presented as raw data; ^** statistically significant from wild type ( ^a,b,c,d Data from 39, 13, 7, and 5 patients, respectively. FLT3 – FMS-like tyrosine kinase 3; IQR – interquartile range; ITD – internal tandem duplication; TKD – tyrosine kinase domain.

Back to the Article